Background: The recent discovery that a combination of noradrenergic and antimuscarinic drugs improved upper airway muscle function during sleep and reduced OSA severity has revitalized interest in pharmacologic therapies for OSA. Research Question: Would 1 week of reboxetine plus oxybutynin (Reb-Oxy) be effective on OSA severity? Study Design and Methods: A randomized, placebo-controlled, double-blind, crossover trial was performed comparing 4 mg reboxetine plus 5 mg oxybutynin (Reb-Oxy) vs placebo in patients with OSA. After a baseline in-laboratory polysomnogram (PSG), patients underwent PSGs after 7 nights of Reb-Oxy and 7 nights of placebo to compare apnea-hypopnea index (AHI), which was the primary outcome. Response rate was based on the percentage of subjects with a ≥ 50% reduction in AHI from baseline. Secondary outcomes included Epworth Sleepiness Scale (ESS) score and psychomotor vigilance test (PVT) values. Home oximetry evaluated overnight oxygen desaturation index (ODI) throughout treatment. Results: Sixteen subjects aged 57 [51-61] years (median [interquartile range]) with a BMI of 30 [26-36] kg/m2 completed the study. Reb-Oxy lowered AHI from 49 [35-57] events per hour at baseline to 18 [13-21] events per hour (59% median reduction) compared with 39 [29-48] events per hour (6% median reduction) with placebo (P <.001). Response rate for Reb-Oxy was 81% vs 13% for placebo (P <.001). Although ESS scores were not significantly lowered, PVT median reaction time decreased from 250 [239-312] ms at baseline to 223 [172-244] ms on Reb-Oxy vs 264 [217-284] ms on placebo (P <.001). Home oximetry illustrated acute and sustained improvement in the oxygen desaturation index on Reb-Oxy vs placebo. Interpretation: The administration of Reb-Oxy greatly decreased OSA severity and increased vigilance. These results highlight potential possibilities for pharmacologic treatment of OSA. Clinical Trial Registration: ClinicalTrials.gov; No.: NCT04449133; URL: www.clinicaltrials.gov

Perger, E., Montemurro, L., Rosa, D., Vicini, S., Marconi, M., Zanotti, L., et al. (2022). Reboxetine plus Oxybutynin for Obstructed Sleep Apnea Treatment A 1-week Randomized, Placebo-controlled, Double-Blind Crossover Trial. CHEST, 161(1 (January 2022)), 237-247 [10.1016/j.chest.2021.08.080].

Reboxetine plus Oxybutynin for Obstructed Sleep Apnea Treatment A 1-week Randomized, Placebo-controlled, Double-Blind Crossover Trial

Perger, Elisa
Primo
;
Vicini, Stefano;Lombardi, Carolina
Co-ultimo
;
Parati, Gianfranco
Co-ultimo
2022

Abstract

Background: The recent discovery that a combination of noradrenergic and antimuscarinic drugs improved upper airway muscle function during sleep and reduced OSA severity has revitalized interest in pharmacologic therapies for OSA. Research Question: Would 1 week of reboxetine plus oxybutynin (Reb-Oxy) be effective on OSA severity? Study Design and Methods: A randomized, placebo-controlled, double-blind, crossover trial was performed comparing 4 mg reboxetine plus 5 mg oxybutynin (Reb-Oxy) vs placebo in patients with OSA. After a baseline in-laboratory polysomnogram (PSG), patients underwent PSGs after 7 nights of Reb-Oxy and 7 nights of placebo to compare apnea-hypopnea index (AHI), which was the primary outcome. Response rate was based on the percentage of subjects with a ≥ 50% reduction in AHI from baseline. Secondary outcomes included Epworth Sleepiness Scale (ESS) score and psychomotor vigilance test (PVT) values. Home oximetry evaluated overnight oxygen desaturation index (ODI) throughout treatment. Results: Sixteen subjects aged 57 [51-61] years (median [interquartile range]) with a BMI of 30 [26-36] kg/m2 completed the study. Reb-Oxy lowered AHI from 49 [35-57] events per hour at baseline to 18 [13-21] events per hour (59% median reduction) compared with 39 [29-48] events per hour (6% median reduction) with placebo (P <.001). Response rate for Reb-Oxy was 81% vs 13% for placebo (P <.001). Although ESS scores were not significantly lowered, PVT median reaction time decreased from 250 [239-312] ms at baseline to 223 [172-244] ms on Reb-Oxy vs 264 [217-284] ms on placebo (P <.001). Home oximetry illustrated acute and sustained improvement in the oxygen desaturation index on Reb-Oxy vs placebo. Interpretation: The administration of Reb-Oxy greatly decreased OSA severity and increased vigilance. These results highlight potential possibilities for pharmacologic treatment of OSA. Clinical Trial Registration: ClinicalTrials.gov; No.: NCT04449133; URL: www.clinicaltrials.gov
Articolo in rivista - Articolo scientifico
antimuscarinic and norepinephrine reuptake inhibitors; OSA; pharmacologic treatment; upper airway; vigilance;
English
20-set-2021
2022
161
1 (January 2022)
237
247
open
Perger, E., Montemurro, L., Rosa, D., Vicini, S., Marconi, M., Zanotti, L., et al. (2022). Reboxetine plus Oxybutynin for Obstructed Sleep Apnea Treatment A 1-week Randomized, Placebo-controlled, Double-Blind Crossover Trial. CHEST, 161(1 (January 2022)), 237-247 [10.1016/j.chest.2021.08.080].
File in questo prodotto:
File Dimensione Formato  
Reb-Oxy Perger CHEST 2021.pdf

accesso aperto

Tipologia di allegato: Submitted Version (Pre-print)
Dimensione 2.15 MB
Formato Adobe PDF
2.15 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/328418
Citazioni
  • Scopus 46
  • ???jsp.display-item.citation.isi??? 44
Social impact